Puma Biotech (PBYI) Tops Q4 EPS by 31c

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.21, $0.31 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $51 million versus the consensus estimate of $46.85 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Alcoa proposes $2.6B notes offering to fund South32 asset deal
• Korn Ferry (KFY) Tops Q1 EPS by 7c, Beats on Revenue; Offers Q2 EPS Guidance